M&A Deal Summary

Recipharm Acquires Arranta Bio

On February 18, 2022, Recipharm acquired life science company Arranta Bio from Ampersand Capital Partners

Acquisition Highlights
  • This is Recipharm’s 12th transaction in the Life Science sector.
  • This is Recipharm’s 3rd transaction in the United States.
  • This is Recipharm’s 2nd transaction in Massachusetts.

M&A Deal Summary
Date 2022-02-18
Target Arranta Bio
Sector Life Science
Buyer(s) Recipharm
Sellers(s) Ampersand Capital Partners
Deal Type Add-on Acquisition
Advisor(s) Morgan Stanley (Financial)
Goodwin Procter (Legal)

Target

Arranta Bio

Watertown, Massachusetts, United States
Arranta Bio is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize therapies targeting the human microbiome. Arranta Bio was founded in 2019 and is based in Watertown, Massachusetts.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Recipharm

Stockholm, Sweden
Category Company
Founded 1995
Sector Life Science
Employees7,383
DESCRIPTION

Recipharm is a global Pharma CDMO providing a full-service offering to leading Pharmaceutical companies and Biotechs globally. Recipharm was founded in 1995 and is based in Stockholm, Sweden.

DEAL STATS #
Overall 18 of 18
Sector (Life Science) 12 of 12
Type (Add-on Acquisition) 9 of 9
State (Massachusetts) 2 of 2
Country (United States) 3 of 3
Year (2022) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-02-18 Vibalogics

Boxborough, Massachusetts, United States

Vibalogics has operated as a specialized global Contract Development and Manufacturing Organization (CDMO) offering process and analytical development, manufacturing, testing, and fill-finish services to innovators developing transformational virotherapy products. Vibalogics GmbH was founded in 2002 and is based in Boxborough, Massachusetts.

Buy -

Seller(S) 1

SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 50 of 55
Sector (Life Science) 22 of 25
Type (Add-on Acquisition) 36 of 38
State (Massachusetts) 13 of 14
Country (United States) 48 of 51
Year (2022) 3 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-02-18 Vibalogics

Boxborough, Massachusetts, United States

Vibalogics has operated as a specialized global Contract Development and Manufacturing Organization (CDMO) offering process and analytical development, manufacturing, testing, and fill-finish services to innovators developing transformational virotherapy products. Vibalogics GmbH was founded in 2002 and is based in Boxborough, Massachusetts.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-03-01 BioEcho Life Sciences

Koln, Germany

BioEcho Life Sciences specializes in nucleic acid sample preparation tools for clinical, biotech, life sciences research, agricultural, and industrial applications. BioEcho Life Sciences was formed in 2016 and is based in Koln, Germany.

Buy -
Mergr

Product

Company

Legal